230 related articles for article (PubMed ID: 34432846)
1. Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.
Weiner F; Schille JT; Hein JI; Wu XF; Beller M; Junghanß C; Murua Escobar H; Nolte I
PLoS One; 2021; 16(8):e0256468. PubMed ID: 34432846
[TBL] [Abstract][Full Text] [Related]
2. Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines.
Schille JT; Nolte I; Packeiser EM; Wiesner L; Hein JI; Weiner F; Wu XF; Beller M; Junghanss C; Murua Escobar H
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31703454
[TBL] [Abstract][Full Text] [Related]
3. Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line.
Weiner F; Schille JT; Koczan D; Wu XF; Beller M; Junghanss C; Hewicker-Trautwein M; Murua Escobar H; Nolte I
BMC Cancer; 2021 Oct; 21(1):1088. PubMed ID: 34625047
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
[TBL] [Abstract][Full Text] [Related]
5. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
Pinto AC; Moreira JN; Simões S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
[TBL] [Abstract][Full Text] [Related]
6. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.
Budman DR; Calabro A; Kreis W
Anticancer Drugs; 2002 Nov; 13(10):1011-6. PubMed ID: 12439335
[TBL] [Abstract][Full Text] [Related]
7. Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines.
Shang D; Liu Y; Liu Q; Zhang F; Feng L; Lv W; Tian Y
Cancer Lett; 2009 Jun; 278(1):82-7. PubMed ID: 19168279
[TBL] [Abstract][Full Text] [Related]
8. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
Wigington DP; Urben CM; Strugnell SA; Knutson JC
Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
[TBL] [Abstract][Full Text] [Related]
9. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
10. Synergistic cytotoxicity of red beetroot (Beta vulgaris L.) extract with doxorubicin in human pancreatic, breast and prostate cancer cell lines.
Kapadia GJ; Rao GS; Ramachandran C; Iida A; Suzuki N; Tokuda H
J Complement Integr Med; 2013 Jun; 10():. PubMed ID: 23828331
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines.
Fruehauf JP; Myers CE; Sinha BK
J Natl Cancer Inst; 1990 Jul; 82(14):1206-9. PubMed ID: 2362291
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.
El-Zawahry A; McKillop J; Voelkel-Johnson C
BMC Cancer; 2005 Jan; 5():2. PubMed ID: 15638938
[TBL] [Abstract][Full Text] [Related]
13. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
14. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
15. Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
Klose K; Packeiser EM; Müller P; Granados-Soler JL; Schille JT; Goericke-Pesch S; Kietzmann M; Murua Escobar H; Nolte I
PLoS One; 2021; 16(9):e0257403. PubMed ID: 34570803
[TBL] [Abstract][Full Text] [Related]
16. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Mimeault M; Venkatraman G; Johansson SL; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Int J Cancer; 2007 Jan; 120(1):160-9. PubMed ID: 17013895
[TBL] [Abstract][Full Text] [Related]
17. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
[TBL] [Abstract][Full Text] [Related]
18. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy.
Li QQ; Wang G; Reed E; Huang L; Cuff CF
Basic Clin Pharmacol Toxicol; 2010 Nov; 107(5):868-76. PubMed ID: 22545969
[TBL] [Abstract][Full Text] [Related]
20. Dichloroacetate enhances adriamycin-induced hepatoma cell toxicity in vitro and in vivo by increasing reactive oxygen species levels.
Dai Y; Xiong X; Huang G; Liu J; Sheng S; Wang H; Qin W
PLoS One; 2014; 9(4):e92962. PubMed ID: 24728083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
